Symvivo
Symvivo Corporation (or simply Symvivo) is a Canadian biotechnology company based in Burnaby, British Columbia.
COVID-19
Symvivo is developing an oral COVID-19 vaccine called bacTRL-Spike.1)
Affiliations
Payments from Symvivo
Payments to Individuals
| Name | Type | Amount | Notes |
|---|---|---|---|
| Soren Gantt | Research | - | Paid to Gantt while he served on the National Advisory Committee on Immunization (NACI)2) |
| Manish Sadarangani | Research | - | Research funding paid to Sadarangani's institution3) |
External links
1)
Symvivo receives funding for COVID-19 vaccine program. (2021, July 19). Symvivo Corporation. https://web.archive.org/web/20220417182902/https://www.symvivo.com/media-2/symvivo-corporation-receives-funding-for-covid-19-vaccine-program
2)
Abu-Raya, B., Gantt, S., & Sadarangani, M. (2020). Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic. Canadian Medical Association Journal, cmaj.201237. https://doi.org/10.1503/cmaj.201237
3)
Evans, T., Sadarangani, M., Maguire, J., Zinszer, K., & Kellner, J. (2022). The importance of pediatric vaccination. COVID-19 Immunity Task Force. https://web.archive.org/web/20220424080020/https://www.covid19immunitytaskforce.ca/wp-content/uploads/2022/03/CITF_CanCOVID_6_Pediatric-vaccination_2022_EN_FINAL-2.pdf